US FDA panel to mull JUPITER-based prevention indication for Crestor
This article was originally published in Scrip
Executive Summary
The US FDA's endocrinologic and metabolic drugs advisory panel will meet on December 15th to consider AstraZeneca's request to add a cardiovascular disease primary prevention claim for Crestor (rosuvastatin) based on data from the JUPITER trial.